These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 23425099)

  • 21. Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers.
    Yonesaka K; Zejnullahu K; Lindeman N; Homes AJ; Jackman DM; Zhao F; Rogers AM; Johnson BE; Jänne PA
    Clin Cancer Res; 2008 Nov; 14(21):6963-73. PubMed ID: 18980991
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epidermal growth factor receptor targeting in cancer: a review of trends and strategies.
    Yewale C; Baradia D; Vhora I; Patil S; Misra A
    Biomaterials; 2013 Nov; 34(34):8690-707. PubMed ID: 23953842
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of advanced cutaneous squamous cell carcinomas with epidermal growth factor receptor inhibitors.
    Alter M; Satzger I; Mattern A; Kapp A; Gutzmer R
    Dermatology; 2013; 227(4):289-94. PubMed ID: 24217470
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
    Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: a dermatology-oncology perspective.
    Lacouture ME; Melosky BL
    Skin Therapy Lett; 2007; 12(6):1-5. PubMed ID: 17762902
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [EGFR/HER1: a target life].
    Viel E; Curtit E; Mansi L; Vignot S
    Bull Cancer; 2012 Feb; 99(2):181-9. PubMed ID: 21684835
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 177Lu-labeled antibodies for EGFR-targeted SPECT/CT imaging and radioimmunotherapy in a preclinical head and neck carcinoma model.
    Liu Z; Ma T; Liu H; Jin Z; Sun X; Zhao H; Shi J; Jia B; Li F; Wang F
    Mol Pharm; 2014 Mar; 11(3):800-7. PubMed ID: 24472064
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of cetuximab after failure of gefitinib in patients with advanced non-small-cell lung cancer.
    Wu JY; Yang CH; Hsu YC; Yu CJ; Chang SH; Shih JY; Yang PC
    Clin Lung Cancer; 2010 Jul; 11(4):257-63. PubMed ID: 20630828
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EGFR targeting of solid tumors.
    Rocha-Lima CM; Soares HP; Raez LE; Singal R
    Cancer Control; 2007 Jul; 14(3):295-304. PubMed ID: 17615536
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The epidermal growth factor receptor as a target for colorectal cancer therapy.
    Lockhart AC; Berlin JD
    Semin Oncol; 2005 Feb; 32(1):52-60. PubMed ID: 15726506
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epidermal growth factor receptor-targeted therapy in colorectal cancer.
    O'dwyer PJ; Benson AB
    Semin Oncol; 2002 Oct; 29(5 Suppl 14):10-7. PubMed ID: 12422309
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epidermal growth factor receptor-targeted therapy in squamous cell carcinoma of the penis: a report of 3 cases.
    Brown A; Ma Y; Danenberg K; Schuckman AK; Pinski JK; Pagliaro LC; Quinn DI; Dorff TB
    Urology; 2014 Jan; 83(1):159-65. PubMed ID: 24238569
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [TBL] [Abstract][Full Text] [Related]  

  • 34. EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma.
    Sundvall M; Karrila A; Nordberg J; Grénman R; Elenius K
    Expert Opin Emerg Drugs; 2010 Jun; 15(2):185-201. PubMed ID: 20415599
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer.
    Bunn PA; Franklin W
    Semin Oncol; 2002 Oct; 29(5 Suppl 14):38-44. PubMed ID: 12422312
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer.
    Herbst RS; Hong WK
    Semin Oncol; 2002 Oct; 29(5 Suppl 14):18-30. PubMed ID: 12422310
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EGFR inhibition as a therapy for head and neck squamous cell carcinoma.
    Loeffler-Ragg J; Schwentner I; Sprinzl GM; Zwierzina H
    Expert Opin Investig Drugs; 2008 Oct; 17(10):1517-31. PubMed ID: 18808311
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical implications of the mechanism of epidermal growth factor receptor inhibitors.
    Marshall J
    Cancer; 2006 Sep; 107(6):1207-18. PubMed ID: 16909423
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer.
    Gui T; Shen K
    Cancer Epidemiol; 2012 Oct; 36(5):490-6. PubMed ID: 22818908
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
    Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; Barón AE; Zeng C; Johnson TK; Bunn PA
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.